hotspot -WSS

hotspot

author：explore 2025-09-30 09:30:03 - browse：4

3d rendered medically accurate illustration of the adrenal gland – biotech and pharma coverage from STAT — Adobe

SAN DIEGO — Neurocrine Biosciences announced on Tuesday that an experimental drug for congenital adrenal hyperplasia succeeded in a late-stage trial, bringing the company a step closer to treating patients with a rare and serious set of genetic disorders that alters their ability to produce key hormones.

In the Phase 3 study, known as CAHtalyst, 182 adults were randomly assigned to receive a placebo or crinecerfont, an oral drug Neurocrine developed to lower male sex hormones patients with the disease produce in excess. Researchers found that, compared to those on placebo, participants who took crinecerfont needed a significantly lower dose of the current standard-of-care treatment, glucocorticoids, after 24 weeks of treatment that they did at the study’s start. And about 63% of participants who took crinecerfont were able to lower their dose of glucocorticoids to levels researchers think would be safer for prolonged use, compared to 18% of those on the placebo.

Neurocine, a San Diego biotech focused on treating rare neurological and endocrine diseases, believes the drug could allow people living with congenital adrenal hyperplasia, or CAH, to avoid some of the more serious side effects of glucocorticoids by allowing them to take lower doses. Long-term use of high doses of these drugs can cause patients to gain weight and put them at risk of diabetes, heart disease, and osteoporosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Feng Zhang suggests Editas didn’t move quickly enough to find product targets

entertainment

WSS

Startling documents reveal new facets of Sacklers' opioid empire

Focused ultrasound for uterine fibroids: an uphill battle

Cancer, immunology, HIV research ensnared in fetal tissue politics

Biohaven protein

Yancopoulos of Regeneron works to expand Dupixent success

Scientists successfully use ultrasound imaging to map brain activity

focus

hotspot

knowledge

Jerome Adams on the need for new antivirals for Covid

'Patient friction coefficient' can gauge a clinical trial's patient burden

Continuity nursing helped my family in our darkest PICU moments

Biotech investment managers search for lucrative opportunities

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Erich Jarvis studies song birds to learn about human stuttering

In Memoriam: Notable people who died in 2023

Biotech investment managers search for lucrative opportunities

Apple is now the first public company to be valued at $3 trillion

Yancopoulos of Regeneron works to expand Dupixent success

entertainment

Diabetes management: Digital health tools fall short, study says

Dark money group runs ads on China biotech bill

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

Heat waves linked to early deliveries, preterm births in new study

AI used to predict Covid

Report: NIH

entertainment

entertainment

hotspot

explore